EVMN

‑ Company to announce EVO756 atopic dermatitis (AD) Phase 2b top-line data in September 2026 ‑ EVO756 migraine prophylaxis Phase 2b dose-ranging trial recently initiated with top-line data in 2027 ‑ EVO301 full Phase 2a positive data set supporting planned Phase 2b trial in AD to be presented at upcoming medical conference ‑ Strong balance sheet, with cash through 2028 to deliver multiple key data readouts across the pipeline PALO ALTO, Calif. & NEW YORK, August 06, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for patients suffering with AD that combine lesion control, itch relief and tolerability. That gap is where we believe EVO756 can make a difference, as it targets neurogenic mast cell biology and non-histaminergic itch. We are excited to deliver top-line Phase 2b data next month. We also believe the underlying biology and market opportunity are especially compelling in migraine prophylaxis and that EVO756 could define the next wave of preventative treatments. We are very excited to have the Phase 2b trial now underway and expect top-line data next year," said Luis Peña, President and Chief Executive Officer at Evommune. "Taken together, these milestones reflect the continued execution of our mission-driven approach to developing transformative therapies for people living with immune-mediated diseases." Recent Business Highlights and Upcoming Milestones EVO756 – Oral MRGPRX2 Antagonist Program Potential first and best-in-class, potent and highly selective small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on both mast cells and peripheral sensory neurons. This dual expression allows MRGPRX2 to uniquely modulate the neurogenic inflammation feedback loop between nerves and immune cells that drive chronic inflammation. Phase 2b Top-Line Data Readout in AD Expected Next Month: The Company expects to report top-line data in September 2026 for the fully-enrolled Phase 2b dose-ranging clinical trial (N=120) in moderate-to-severe AD patients. The primary endpoint of the trial is percent change in Eczema Area and Severity Index (EASI) from baseline at Week 12. Key secondary endpoints include the proportion of patients achieving ≥50% and ≥75% reductions in EASI, and evaluation of Pruritus-NRS, a tool used to assess the severity of itching. Migraine Prophylaxis Phase 2b Trial Now Underway with Top-Line Data Anticipated in 2027: In July 2026, the Company initiated a global randomized, double-blind, placebo-controlled Phase 2b dose-ranging clinical trial in migraine prophylaxis. Top-line data from the trial are expected in 2027. The trial is evaluating EVO756 in adults with refractory migraine experiencing ≥6 migraine days per month. Approximately 330 patients will be randomized across two active dose arms and placebo for 12 weeks of treatment. The trial is exploring daily doses of up to 100 mg. The primary endpoint of the Phase 2b trial is the mean change from baseline in monthly migraine days (MMD). Key secondary endpoints include the proportion of patients achieving ≥50% and ≥75% reductions in MMD, change from baseline in monthly headache days and monthly acute migraine medication use. Prioritization of EVO756 Development Outside of CSU: In June 2026, the Company reported top-line results from a randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. The safety profile observed demonstrated safe and well-tolerated doses of EVO756. Following these results, Evommune has discontinued development of EVO756 in CSU and will continue to focus development efforts on AD and migraine. EVO301 – Injectable IL-18 Binding Protein Fusion Protein Program Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies. Full Results from Positive Phase 2a Trial in AD to be Presented at Upcoming Medical Conference: The full dataset from the positive Phase 2a trial in adult patients with moderate-to-severe AD will be presented at an upcoming medical conference, where the Company plans disclosure on key secondary endpoints as well as key biomarker data showing Th2 and non-Th2 biomarker impact supporting the breadth of IL-18 inhibition in AD. Phase 2b AD Trial to Initiate in mid-2027: The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three subcutaneous dosing regimens of EVO301 tested over a 16-week treatment period. Manufacturing is ongoing and following completion of standard scale-up and toxicology activities, the trial is anticipated to begin in mid-2027. Evaluating Additional Indication Expansion Opportunities: The Company continues to evaluate additional indications for EVO301, including ulcerative colitis and certain cardiovascular-related inflammatory conditions, as potential new Phase 2 clinical trials. Second Quarter 2026 Financial Results Cash, Cash Equivalents and Investments: As of June 30, 2026, the Company had cash, cash equivalents and investments of $288.0 million, compared to $216.7 million as of December 31, 2025. Revenue: Revenue was zero for the three and six months ended June 30, 2026, compared to zero and $3.0 million for the three and six months ended June 30, 2025, attributable to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan. Research and Development Expenses: Research and development expenses were $26.4 million and $43.7 million for three and six months ended June 30, 2026, compared to $19.6 million and $34.0 million for the three and six months ended June 30, 2025. General and Administrative Expenses: General and administrative expenses were $8.5 million and $15.1 million for the three and six months ended June 30, 2026, compared to $3.4 million and $7.0 million for the three and six months ended June 30, 2025. Net Loss: Net loss totaled $32.2 million and $53.9 million for the three and six months ended June 30, 2026, compared to $13.6 million and $28.1 million for the three and six months ended June 30, 2025. About Evommune, Inc. Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, and the design, objectives, initiation, timing, progress and results of the Phase 2b clinical trials evaluating EVO756 AD and in migraine and the Phase 2b trial evaluating EVO301 in AD; anticipated cash runway through 2028; and continued advancement of the Company's portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260806006411/en/ Contacts Media: Paul [email protected] Investors: Sarah [email protected]

- Trial did not meet the primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks - Evommune to continue development of EVO756 in Atopic Dermatitis and Migraine PALO ALTO, Calif. & NEW YORK, June 29, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRGPRX2 antagonist, EVO756, in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The Phase 2b trial enrolled 160 moderate-to-severe antihistamine-refractory CSU patients in the United States, Europe, Canada and Japan. Participants received one of three active dose regimens or placebo. The study did not meet the primary endpoint of mean change in a patient’s Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. "EVO756 previously delivered positive Phase 2 data in chronic inducible urticaria and showed clear target engagement in the Phase 1 trial, however, the lack of efficacy demonstrated at Week 12 in this Phase 2b trial does not support further development of EVO756 for CSU," said Dr. Eugene Bauer, Chief Medical Officer of Evommune. "We are evaluating EVO756 in additional indications, and this Phase 2b trial confirmed safe and well tolerated doses that warrant these further studies. We are sincerely grateful to the patients, clinicians and administrators who participated in this trial." "While we are disappointed with the trial results in this indication, we continue to believe that modulation of MRGPRX2 represents a new potential therapeutic option to reduce inflammation and provide rapid relief of symptoms. We remain on track to report top-line Phase 2b data for EVO756 in atopic dermatitis (AD) in the third quarter of 2026. We have also initiated screening in a Phase 2b trial of EVO756 in migraine prophylaxis, and expect patient dosing to commence imminently. For EVO301, our IL-18BP fusion protein, we recently reported positive Phase 2a proof-of-concept data in AD and look forward to moving the program into a robust Phase 2b AD trial," said Luis Peña, President and Chief Executive Officer at Evommune. "With a strong cash position supporting our anticipated operations through 2028, we believe we are well positioned to execute on key milestones and further advance our pipeline of therapies addressing chronic inflammatory diseases." About EVO756 EVO756 is a first-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Evommune seeks to produce the first MRGPRX2-targeted oral treatment for chronic inflammatory diseases, including atopic dermatitis (AD) and migraine, as well as additional possible indication expansions. About EVO301 EVO301 is a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity. EVO301 facilitates more efficient tissue distribution and improved binding affinity and specificity relative to existing attempts to antagonize or inhibit the IL-18 pathway, including traditional mAbs. In addition, EVO301 incorporates several distinguishing design features, including selective and high binding affinity of native human IL-18BP and binding to serum albumin, smaller molecular weight, extended half-life for the neutralization of IL-18, and lower potential for immunogenicity. Evommune believes the distinct mechanism and modality of EVO301 complement those of EVO756, providing multiple, potentially synergistic avenues to bring innovative therapeutics to the large, underserved and rapidly expanding population of patients suffering from chronic inflammatory diseases. About Evommune, Inc. Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway through 2028; and the Company’s ability to execute on key milestones and the continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260629470075/en/ Contacts Media:Paul [email protected] Investors:Sarah [email protected]

‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ‑ Phase 2b clinical trial evaluating a subcutaneous formulation of EVO301 in AD planned, following positive proof-of-concept (POC) data reported in February 2026 ‑ Plans to initiate a Phase 2b dose-ranging clinical trial of EVO756 in migraine prophylaxis in mid-2026 PALO ALTO, Calif. & NEW YORK, May 07, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for EVO756 in CSU in June and in AD in the third quarter of 2026. We also expect to initiate a Phase 2b clinical trial in a third indication, migraine prophylaxis, in mid-2026, where we believe the biology and opportunity are both very compelling. For EVO301, we recently reported positive Phase 2a proof-of-concept data in AD and look forward to presenting more data from that trial at an upcoming medical meeting," said Luis Peña, President and Chief Executive Officer at Evommune. "With a strong cash position expected to support our operations through 2028, we believe we are well positioned to execute on key milestones and further advance our pipeline of therapies addressing inflammatory diseases where the biology is strong, the patient need is clear, and the path to development is well defined." Business Highlights, Recent Developments and Upcoming Milestones EVO756 – Oral MRGPRX2 Antagonist Program Potential first and best-in-class, potent and highly selective small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on both mast cells and peripheral sensory neurons. This dual expression allows MRGPRX2 to uniquely modulate the neurogenic inflammation feedback loop between nerves and immune cells that drive chronic inflammation. Upcoming Phase 2b Top-Line Data Readout in CSU: Enrollment is complete in a Phase 2b dose-ranging clinical trial (N=160) in moderate-to-severe CSU and the Company expects to report top-line results in June 2026. Upcoming Phase 2b Top-Line Data Readout in AD: Enrollment is complete in a Phase 2b dose-ranging clinical trial (N=120) in moderate-to-severe AD patients and the Company expects to report top-line results in the third quarter of 2026. Highlighted Role of MRGPRX2 in Migraine and Planned Phase 2b Development Program: The Company recently hosted a virtual event, alongside key opinion leaders, overviewing the role of MRGPRX2 in migraine and its plans to initiate a Phase 2b dose-ranging clinical trial in migraine prophylaxis in mid-2026. Top-line data from the trial are anticipated in 2027. New Translational Data to be Presented at Two Upcoming Scientific Conferences: At the Federation of Clinical Immunology Societies (FOCIS) Annual Meeting, being held June 9-12, 2026 in San Francisco, CA, Evommune will present two posters: the first highlighting shared pathology data in chronic inducible urticaria (CIndU) and CSU patient samples, and the second providing an comprehensive and unprecedented in silico assessment of patient samples identifying MRGPRX2 as a persistent driver of disease in AD. The Company will also present a poster highlighting the pivotal role of MRGPRX2 impacting both meningeal mast cells and trigeminal neurons in migraine pathophysiology at the American Headache Society (AHS) Annual Scientific Meeting being held June 4-7, 2026 in Orlando, FL. EVO301 – Injectable IL-18 Binding Protein Fusion Protein Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies. Subcutaneous Formulation Work Complete: Evommune has completed work on a high-concentration subcutaneous formulation of EVO301 and manufacturing has been initiated. Phase 2b Trial to Initiate in Mid-2027: The Company plans to build on the positive Phase 2a POC data by optimizing the subcutaneous dosing regimen in the Phase 2b clinical trial to explore the potential for even further improvement in AD patient outcomes. The planned Phase 2b, placebo-controlled, dose-ranging clinical trial is expected to include at least three dosing regimens of EVO301 tested over a 16-week treatment period, with a planned trial start in mid-2027 following completion of standard scale-up and toxicology activities. Evaluating Additional Indication Expansion Opportunities: The Company continues to evaluate additional indications for EVO301, including ulcerative colitis, certain cardiovascular-related inflammatory conditions and food allergy, as potential new Phase 2 clinical trials. Upcoming Preclinical Data Presentation at Society for Investigative Dermatology (SID) 2026 Annual Meeting: The Company will present preclinical data highlighting the mechanism of action of IL-18 inhibition for the treatment of AD and the uniqueness of EVO301’s binding protein approach at the upcoming SID Annual Meeting being held May 13-16, 2026 in Chicago, IL. "We are excited to present a robust set of preclinical and translational findings at upcoming scientific conferences," said Dr. Jeegar Patel, Chief Scientific Officer at Evommune. "We continue to build a compelling body of evidence supporting shared disease biology across CIndU and CSU, while further elucidating the role and expression of the MRGPRX2 receptor in AD. Importantly, our migraine-focused research expands this understanding into the neuroinflammatory setting, demonstrating MRGPRX2’s involvement in both meningeal mast cells and trigeminal neurons. Collectively, these findings reinforce our conviction in MRGPRX2 as a highly differentiated and potentially broad therapeutic target, continuing to build momentum as we look ahead to upcoming top-line Phase 2b data in CSU next month." First Quarter 2026 Financial Results Cash, Cash Equivalents and Investments: As of March 31, 2026, the Company had cash, cash equivalents and investments of $307.0 million, compared to $216.7 million as of December 31, 2025. Revenue: Revenue was zero for the first quarter ended March 31, 2026, compared to $3.0 million for the same period in 2025, attributable to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan. Research and Development Expenses: Research and development expenses were $17.3 million for the first quarter ended March 31, 2026, compared to $14.4 million for the same period in 2025. General and Administrative Expenses: General and administrative expenses were $6.6 million for the first quarter ended March 31, 2026, compared to $3.7 million for the same period in 2025. Net Loss: Net loss totaled $21.7 million for the first quarter ended March 31, 2026, compared to $14.6 million for the same period in 2025. About Evommune, Inc. Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway through 2028; and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company’s Annual Report on Form 10-K, filed with the SEC on March 5, 2026, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260507281814/en/ Contacts Media: Paul Laland [email protected] Investors: Sarah McCabe [email protected]

– Reported positive top-line data from Phase 2a proof-of-concept (POC) trial of EVO301 in atopic dermatitis (AD) – EVO756 on track to report Phase 2b top-line data in chronic spontaneous urticaria (CSU) and AD in 2Q26 and 2H26, respectively – Strengthened balance sheet with $125 million private placement to support additional clinical milestones and extend runway through 2028 PALO ALTO, Calif. & NEW YORK, March 05, 2026--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a compelling approach for patients living with AD. We look forward to advancing the program forward and exploring an optimal dosing regimen for this potentially front-line biologic for AD," said Luis Peña, President and Chief Executive Officer at Evommune. "We’ve nearly completed patient enrollment in the EVO756 Phase 2b trial in CSU, and plan to share top-line data in the second quarter. Additionally, the EVO756 Phase 2b trial in AD remains on track to report data in the second half of the year. MRGPRX2 antagonism is unique in its potential to modulate both mast cells and sensory neurons and we are eager to show the potential of MRGPRX2 inhibition in patients suffering from these debilitating diseases." Mr. Peña continued, "We recently strengthened our cash position with a $125 million private placement, which increases our ability to move EVO301 into deeper development and to expand our development programs as we look to make a major impact in the treatment of chronic inflammatory diseases. We continue to execute across our pipeline, underscoring our focus on delivering new medicines to patients, and I am very proud of the work being done by the entire Evommune team." Business Highlights, Recent Developments and Upcoming Milestones EVO756 – Oral MRGPRX2 Antagonist Program: First-in-class, potent and highly selective oral small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Phase 2b Top-Line Data Readouts in CSU and AD Expected in 2026: A Phase 2b dose-ranging trial (N=160) in moderate-to-severe CSU was initiated in April 2025, and the Company expects to report top-line results in the second quarter of 2026. The Company also initiated a Phase 2b dose-ranging trial (N=120) in moderate-to-severe AD patients in August 2025 and expects to report top-line results in the second half of 2026. Indication Expansion in 2026: The Company plans to initiate a Phase 2b trial in migraine in mid-2026 and continues to evaluate and explore potential additional indications for EVO756, including asthma, interstitial cystitis, irritable bowel syndrome and pruritus. EVO301 – Injectable IL-18 Binding Protein Fusion Protein: Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies. Reported Positive Phase 2a Top-line POC Data: In February 2026, Evommune announced positive top-line results from a 70-patient, randomized, double-blind, placebo-controlled Phase 2a trial of EVO301 in moderate-to-severe AD. The trial met its primary endpoint and EVO301 showed statistically significant EASI reductions vs. placebo at weeks 4, 8 and 12, with 33% placebo-adjusted improvement in EASI and 23% placebo-adjusted IGA 0/1 at week 12, after only two doses of EVO301 (day 1 and week 4). EVO301 was well tolerated with no related serious or severe adverse events and no observed conjunctivitis. Full results from the Phase 2a trial will be presented at a future scientific conference. Phase 2b Trial Planning: The POC data support plans to move a subcutaneous formulation of EVO301 into a Phase 2b dose-ranging and Phase 3-enabling trial where the Company plans to expand on the POC data set by optimizing the dose and regimen to evaluate and explore the potential for even further improvement in AD patient outcomes. Planning for this trial is underway and the Company plans to share further details about the trial-design in the near future. Advancing Toward Phase 2 Trial Initiation in a New Indication: The Company is also evaluating potential additional indications for EVO301, including ulcerative colitis and certain cardiovascular-related inflammatory conditions. Recent Corporate Highlights Closed $125 Million Private Placement: In February 2026, Evommune entered into a securities purchase agreement to sell its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. This additional capital allows Evommune to support additional clinical milestones and extend its cash runway through 2028. Upcoming Events Wednesday, March 11, 2026: Fireside chat at 1:00 p.m. ET at the Leerink Partners Global Healthcare Conference in Miami, FL. A live webcast of the presentation will be available on the Investors & Media page of the Company’s website at www.evommune.com. Fourth Quarter and Full Year 2025 Financial Results Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments were $216.7 million as of December 31, 2025, compared to $72.0 million as of December 31, 2024. Cash, cash equivalents and investments as of December 31, 2025, along with net proceeds from the February 2026 private placement, are expected to provide cash runway through 2028. Revenue: Revenue was $0 million and $13.0 million for the fourth quarter and full year ended December 31, 2025, respectively, compared to $0 million and $7.0 million for the fourth quarter and full year ended December 31, 2024, respectively. The increase in revenue was related to the strategic collaboration with Maruho Co., Ltd. related to licensing EVO756 in Japan. Research and Development Expenses: Research and development expenses were $20.4 million and $74.0 million for the fourth quarter and full year ended December 31, 2025, respectively, compared to $17.8 million and $64.2 million for the fourth quarter and full year ended December 31, 2024, respectively. General and Administrative Expenses: General and administrative expenses were $9.3 million and $20.0 million for the fourth quarter and full year ended December 31, 2025, respectively, compared to $3.6 million and $12.8 million for the fourth quarter and full year ended December 31, 2024, respectively. Net Loss: Net loss totaled $28.3 million and $68.9 million for the fourth quarter and full year ended December 31, 2025, respectively, compared to $20.7 million and $66.8 million for the fourth quarter and full year ended December 31, 2024, respectively. About Evommune, Inc. Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the potential therapeutic benefit of EVO756 and EVO301, the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; anticipated cash runway through 2028; and continued advancement of the Company’s portfolio. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company’s Quarterly Report on Form 10-Q, filed with the SEC on December 11, 2025, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260305033785/en/ Contacts Media: Paul Laland [email protected] Investors: Sarah McCabe [email protected]

- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU) - Well capitalized to deliver on key milestones following completion of initial public offering (IPO), raising $172.5 million in gross proceeds, including the full exercise of the underwriters’ option to purchase additional shares PALO ALTO, Calif., December 11, 2025--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. "The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expected next year. Atopic dermatitis (AD) remains the most prevalent autoimmune disease, and the need for more treatment options is urgent. We’re advancing two programs targeting novel mechanisms designed to give physicians and patients new tools to treat AD, if approved. MRGPRX2 antagonism is unique in its potential to change the paradigm as the first target that modulates both mast cells and sensory neurons, and IL‑18 inhibition has the potential to become a front-line biologic target in AD," said Luis Peña, President and Chief Executive Officer at Evommune. "We also anticipate reporting top-line Phase 2b data from the EVO756 CSU trial in the first half of 2026 and are optimistic that these data will support ongoing development in CSU, which continues to be underserved by existing treatment options and represents a significant market opportunity," added Mr. Peña. "Overall, we are energized by the progress and execution across our pipeline, which has broad potential for patients suffering from a range of chronic inflammatory diseases. By identifying and addressing critical gaps in the current treatment landscapes, our team is working diligently to continue to discover and add to the pipeline, with a goal of delivering therapies that provide rapid symptom relief and safe, durable resolution of underlying chronic inflammatory disease," said Jeegar Patel, Ph.D., Chief Scientific Officer at Evommune. Pipeline Highlights EVO756: Potent and highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons. Presented Full Phase 2 Data in Chronic Inducible Urticaria at EADV: At the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France in September 2025, the Company presented additional positive data from its Phase 2 trial of EVO756 in adults with chronic inducible urticaria (CIndU). The data highlight EVO756's differentiated mast cell dual mechanism, with responses observed as early as one week and after four weeks of oral treatment. Additionally, EVO756 was generally well-tolerated. https://ir.evommune.com/news-events/press-releases/detail/85/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress Two Phase 2b Top-Line Data Readouts Anticipated in 2026 in CSU and AD: A Phase 2b dose-ranging trial (n=160) in moderate-to-severe CSU was initiated in April 2025, and the Company expects to report top-line results in the first half of 2026. The Company also initiated a Phase 2b dose-ranging trial (n=120) in moderate-to-severe atopic dermatitis (AD) patients in August 2025 and expects to report top-line results in the second half of 2026. Expansion into Additional Indications: The Company continues to evaluate and explore potential additional indications for EVO756, including migraine, irritable bowel syndrome and asthma. EVO301: Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies. Phase 2a Top-Line Data Readout Expected in 1H26: The Company initiated a Phase 2 trial (n=60) of EVO301 in adult patients with moderate-to-severe AD in March 2025. This trial is fully enrolled, and the Company expects to report top-line results in the first half of 2026. Expansion into Additional Indications: The Company continues to evaluate and explore potential additional indications for EVO301 including ulcerative colitis. Recent Corporate Highlights In November 2025, the Company completed its IPO of 10,781,250 shares of its common stock at a public offering price of $16.00 per share, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $172.5 million. Shares began trading on the New York Stock Exchange on November 6, 2025, under the symbol "EVMN." Third Quarter 2025 Financial Results Cash, Cash Equivalents and Investments: As of September 30, 2025, the Company had cash, cash equivalents and investments of $76.0 million, compared to $72.0 million as of December 31, 2024. Revenue: Revenue was $10.0 million for the quarter ended September 30, 2025, compared to zero for the quarter ended September 30, 2024, all related to the Company’s strategic collaboration with Maruho related to licensing EVO756 in Japan. Research and Development Expenses: Research and development expenses were $19.6 million for the third quarter of 2025 as compared to $13.3 million for the third quarter of 2024. General and Administrative Expenses: General and administrative expenses were $3.7 million for the third quarter of 2025 as compared to $3.2 million for the third quarter of 2024. Net Loss: Net loss totaled $12.5 million for the third quarter of 2025 as compared to $15.9 million for the third quarter of 2024. About Evommune, Inc. Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are "forward-looking statements." These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; and the expected market opportunity for its lead programs. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the Company’s final prospectus for its initial public offering, filed with the SEC on November 6, 2025, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20251211387121/en/ Contacts Media: Paul Laland [email protected] Investors: Sarah McCabe [email protected]